Inside Precision Medicine December 8, 2023
Chris Anderson

Researchers at Case Western Reserve University say that a class of diabetes drugs used to treat type 2 diabetes may reduce the risk of the development of colorectal cancer (CRC). The drugs, called glucagon-like peptide-1 receptor agonists, or GLP-1 RAs are medications that are given by injection to lower blood sugars, improve insulin sensitivity, and can help manage weight. This class of drugs has also recently taken off as a weight loss medication.

Results of the study were published this week in the journal JAMA Oncology.

“Our results clearly demonstrate that GLP-1 RAs are significantly more effective than popular anti-diabetic drugs, such as Metformin or insulin, at preventing the development of CRC,” said co-lead researcher Nathan Berger, a professor at...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Health System / Hospital, Pharma, Pharma / Biotech, Provider, Survey / Study, Trends
CEO of McLaren Bay Region steps down
AHA expresses concerns with UHG program in response to cyberattack on Change Healthcare
Health system leaders join Microsoft-backed nonprofit
AHA urges Congress to provide support to help minimize further fallout from Change Healthcare attack
Christus installs Epic at 6 hospitals

Share This Article